Filing Flows › Nautilus Biotechnology (NAUT) › Q3 2026
Nautilus Biotechnology (NAUT) Q3 2026 earnings results (third quarter 2026)
10-Q filed Oct 27, 2026
Nautilus Biotechnology (NAUT) reported revenue of $234K for the third quarter 2026 (Q3 2026) and +23% from the quarter before.
Nautilus Biotechnology, Q3 2026: revenue $234K, net loss $15.6M, operating cash flow −$13.3M. The chart follows the revenue to costs, profit and cash.
| Q3 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $234K | +23% | — |
| Operating profit | −$15.6M | — | — |
| Net earnings | −$15.6M | — | — |
| Operating cash flow | −$13.3M | — | — |
What changed
Revenue was $234K in Q3 2026, up 23% from the previous quarter.
Operating costs exceeded revenue by $15.6M, an operating margin of -6682.1%. The quarter ended with a net loss of $15.6M, wider than the previous quarter's $14.5M loss.
Operating cash flow was −$13.3M. Non-cash charges added back $200K of depreciation and $1.3M of share-based compensation. Working capital and other items added $863K. Capital expenditures of $1.4M exceeded it, leaving free cash flow of −$14.7M.
Questions
What was Nautilus Biotechnology's revenue in the third quarter 2026?
Nautilus Biotechnology (NAUT) reported revenue of $234K for the third quarter 2026 (Q3 2026) and +23% from the quarter before.